Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 2 of 30

RECRUITING NA

Exploring Water-free Sodium Storage

NCT06872645
RECRUITING Phase 2

Circulating Tumor DNA

NCT06923527
RECRUITING NA

Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder

NCT06834217
RECRUITING Phase 2

MDMA in Borderline Personality Disorder

NCT06683014
RECRUITING NA

T1CARE: A Trial of a Novel Intervention to Address Social Determinants of Health in Young Adults With Type 1 Diabetes

NCT07059806
RECRUITING

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

NCT07155252
RECRUITING Phase 1

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07027488
RECRUITING Phase 1

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

NCT06070649
RECRUITING NA

Nourishing Hope: The Impact of Nutrition in Cancer Treatment and Recovery in Maine

NCT07076004
RECRUITING

Preoperative Exercise Testing and Perioperative Outcomes

NCT07519733
RECRUITING

Psychedelic Virtual Reality

NCT06581263
RECRUITING NA

Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation

NCT06407427
RECRUITING Early Phase 1

Merck IIT: RRP Pembro and Lenvatinib

NCT04645602
RECRUITING NA

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

NCT06967701
RECRUITING Phase 2

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

NCT06953882
RECRUITING

Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974

NCT07488819
RECRUITING Phase 2

Pilot fMRI Studies of Aging-Related Effects of THC

NCT06647524
RECRUITING NA

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

NCT07019259
RECRUITING NA

Effects of Novel E-cigarette Constituents on Adults TCORS 3.0

NCT05932745
RECRUITING Phase 2

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

NCT06750484
RECRUITING Phase 2

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

NCT06006143
RECRUITING NA

Video-Based Pelvic Floor Muscle Therapy

NCT06689891
RECRUITING Phase 1

Acute Effects of THC in Older Adult

NCT06948136
RECRUITING Phase 2

Digoxin In NASH (CODIN)

NCT06588699
RECRUITING Phase 1

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

NCT06160284
RECRUITING Early Phase 1

Mechanistic Studies of Psilocybin in Headache Disorders

NCT06464367
RECRUITING Early Phase 1

Regulation of Brain Glucose Metabolism in Type 1 Diabetes

NCT05317455
RECRUITING NA

rTMS as Add on Treatment for Substance Use Disorders

NCT06963476
RECRUITING Phase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434
RECRUITING NA

Change 4 Better (C4B)

NCT06963931
RECRUITING NA

Portable Rapid Imaging for Medical Emergencies

NCT06930534
RECRUITING Phase 2

Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse

NCT06609369
RECRUITING NA

tDCS for Laryngeal Dystonia

NCT06830174
RECRUITING NA

Submaximal Cardiopulmonary Exercise Testing for Detection of Myocardial Injury After Noncardiac Surgery

NCT06474754
RECRUITING NA

Adaptive Decision Support for Addiction Treatment Master

NCT06799117
RECRUITING Phase 2

Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder

NCT06446765
RECRUITING Phase 2

Efficacy of Guselkumab in Treating Hailey Hailey Disease

NCT06651489
RECRUITING NA

Effects of Enriched Parent-Infant Interaction on Health in Early Life

NCT06248125
RECRUITING Phase 2

Substance Misuse and Family Violence Treatment Fathers

NCT06650267
RECRUITING

Measuring Brain Health Using Low-Field Portable MRI

NCT06533631
RECRUITING

Opioid Use Disorder and Pain

NCT06800703
RECRUITING Phase 3

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

NCT06713616
RECRUITING Phase 2

Kick-Nic! Youth Quit Vaping App

NCT06662305
RECRUITING NA

Stress and Pain in People Living With HIV

NCT06784908
RECRUITING Phase 1

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)

NCT06513819
RECRUITING

fMRI and Opioid Abstinence

NCT06651333
RECRUITING

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
RECRUITING Phase 3

Standard Versus High Dose ED-Initiated Buprenorphine Induction

NCT06494904
RECRUITING NA

Craving Network Neurofeedback

NCT06426693
RECRUITING Phase 1

Patient Controlled Administration of Liquid Acetaminophen

NCT06498713
← Previous Page 2 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

Therapeutic Areas

Opioid Use Disorder 19
Obesity 15
Alcohol Use Disorder 13
Heart Failure 13
HIV 13
Type 1 Diabetes 10
Schizophrenia 10
Healthy 10
Nicotine Dependence 9
Major Depressive Disorder 9

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.